Roche Products has received regulatory approval for the removal of restrictions for using Eucardic (carvedilol) tablets in heartfailure. Initiation and uptitration of carvedilol in the treatment of heart failure need not be under the supervision of a hospital physician. The requirement to monitor patients for two to three hours after the first dose and at each subsequent dose increase has been removed. The contraindication of using carvedilol in severe heart failure has been amended to a contraindication in unstable decompensated patients onlyand a warning in relation to stable, severe heart failure.